Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function

Onkologie

Volumn 26, Issue 6, 2003, Pages 578-580

  Schull B ^a   Scheithauer, W ^a   Kornek, G V ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer, metastatic; Capecitabine; Hyperbilirubinemia; Jaundice; Xeloda

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GEMCITABINE; GOSERELIN; TAMOXIFEN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BREAST CARCINOMA; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER FUNCTION; LIVER METASTASIS; NAUSEA; SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERBILIRUBINEMIA; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LUNG NEOPLASMS; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PRODRUGS; RETREATMENT; SALVAGE THERAPY;

EID: 0347987886     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074155     Document Type: Article

References (10)

1. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998;339:974-984.
2. Pritchard KI: Liver metastases: Can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? Eur J Cancer 1997;33(Suppl 7):S11-S14.
3. Schüller J, Cassidy J, ReignerBG, Durston S, Roos B, Ishitsuka H, Utoh M, Dupont E: Tumor selectivity of Xeloda in colorectal cancer patients. Proc Am Soc Clin Oncol 1997;16:227.
4. Frings S: Capecitabine - a novel oral tumor-activated fluoropyrimidine. Onkologie 1998;21:451-458.
5. Twelves C, Glynne-Jones R, Cassidy J, Schüller J, Goggin T, Roos B, Banken L, Utoh M, Weidekamm E, Reigner B: Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capectiabine and its metabolites. Clin Cancer Res 1999;5:1696-1702.
6. Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W: Treatment of advanced breast cancer with docetaxel and gemcitabine with or without huaman granulocyte colony-stimulating factor. Clin Cancer Res 2002;8:1051-1056.
7. Fumoleau P: Treatment of patients with liver metastases. Anticancer Drugs 1996;7(Suppl 2):21-23.
8. Gurevich I, Akerley W: Treatment of the jaundiced patient with breast cancer: Case report and alternate therapeutic strategies. Cancer 2001;91:660-663.
9. Stemmler J, Heinemann V, Schalhorn A: Capecitabine as second-line treatment for metastastic cholangiocarcinoma: A report of two cases. Onkologie 2002;25:182-184.
10. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Browns CS, Griffin T: A multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.